Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-06-13
2006-06-13
Hartley, Michael (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S510000, C549S511000
Reexamination Certificate
active
07060724
ABSTRACT:
Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include the coating of implantable stents for prevention of restenosis.
REFERENCES:
patent: 4356166 (1982-10-01), Peterson et al.
patent: 4942184 (1990-07-01), Haugwitz et al.
patent: 4943579 (1990-07-01), Vishnuvajiala et al.
patent: 4960790 (1990-10-01), Stella et al.
patent: 5059699 (1991-10-01), Kingston et al.
patent: 5087616 (1992-02-01), Myers et al.
patent: 5169933 (1992-12-01), Anderson et al.
patent: 5219564 (1993-06-01), Zallpsky et al.
patent: 5340817 (1994-08-01), Wall et al.
patent: 5362831 (1994-11-01), Mongelli et al.
patent: 5380751 (1995-01-01), Chen et al.
patent: 5422364 (1995-06-01), Nicolaou et al.
patent: 5468769 (1995-11-01), Klein et al.
patent: 5473055 (1995-12-01), Mongelli et al.
patent: 5489525 (1996-02-01), Pastan
patent: 5545880 (1996-08-01), Bu et al.
patent: 5569720 (1996-10-01), Mongelli et al.
patent: 5583153 (1996-12-01), Brahn
patent: 5607659 (1997-03-01), Gustavson et al.
patent: 5614549 (1997-03-01), Greenwald et al.
patent: 5621001 (1997-04-01), Canetta et al.
patent: 5626862 (1997-05-01), Brem et al.
patent: 5629433 (1997-05-01), Zheng et al.
patent: 5641803 (1997-06-01), Carretta et al.
patent: 5646159 (1997-07-01), Wall et al.
patent: 5648506 (1997-07-01), Desai et al.
patent: 5716981 (1998-02-01), Hunter et al.
patent: 5719265 (1998-02-01), Mongelli et al.
patent: 5730968 (1998-03-01), Butterfield et al.
patent: 5733925 (1998-03-01), Kunz et al.
patent: 5762909 (1998-06-01), Uzgiris
patent: 5773522 (1998-06-01), Angelucci et al.
patent: 5776925 (1998-07-01), Young et al.
patent: 5783178 (1998-07-01), Kabanov et al.
patent: 5811447 (1998-09-01), Kunz et al.
patent: 5837673 (1998-11-01), Tsujihara et al.
patent: 5846565 (1998-12-01), Brem et al.
patent: 5854006 (1998-12-01), Hanigan et al.
patent: 5873904 (1999-02-01), Ragheb et al.
patent: 5880131 (1999-03-01), Greenwald et al.
patent: 5886026 (1999-03-01), Hunter et al.
patent: 5892043 (1999-04-01), Tsujihara et al.
patent: 5916896 (1999-06-01), Wall et al.
patent: 5977163 (1999-11-01), Li et al.
patent: 5981568 (1999-11-01), Kunz et al.
patent: 6005020 (1999-12-01), Loomis
patent: 6011042 (2000-01-01), Greenwald et al.
patent: 6028164 (2000-02-01), Loomis
patent: 6127355 (2000-10-01), Greenwald et al.
patent: 6218367 (2001-04-01), Jacob
patent: 6262107 (2001-07-01), Li et al.
patent: 2001/0034363 (2001-10-01), Li et al.
patent: 2002/0016265 (2002-02-01), Bhatt et al.
patent: 2002/0155992 (2002-10-01), Xu
patent: 0589281 (1996-03-01), None
patent: 0558959 (1997-04-01), None
patent: 0604910 (2000-06-01), None
patent: 5286868 (1993-11-01), None
patent: WO 93/10121 (1993-05-01), None
patent: WO 95/03036 (1995-02-01), None
patent: WO 95/13053 (1995-05-01), None
patent: WO 96/25176 (1996-08-01), None
patent: WO 97/33552 (1997-09-01), None
patent: WO 99/17804 (1999-04-01), None
patent: WO 99/49901 (1999-10-01), None
patent: WO 00/61788 (2000-10-01), None
patent: WO 01/70275 (2001-09-01), None
Balog et al., “Total Synthesis of (-) Epothilone A,”Angew. Chem. Int. Ed. Engl., vol. 35, 1996, pp. 2801-2803 © VCH Verlagsgesellschaft mbH, Weinheim.
Bartoli et al., “In Vitro and In Vivo Anitumoral Activity of Free, and Encapsulated Taxol,”J. Microencapsulation, vol. 7, 1990, pp. 191-197 © Taylor & Francis Ltd.
Bom et al., “The Novel Silatecan 7-tert-Butyldimethylsliyl-10-hydroxycamptothecin Displays High Lipophilicity, Improved Human Blood Stability, and Potent Anticancer Activity,”Journal of Medicinal Chemistry, vol. 43, No. 21, 2000, pp. 3970-3980, © American Chemical Society.
Borman, S., “Epothilone Epiphany: Total Syntheses,”C&EN, vol. 74, 1996, pp. 24-26 © American Chemical Society.
Caiolfa et al., “Polymer-bound camptohecin: Initial biodistribution and antitumor activity studies,”Journal of Controlled Release, vol. 65, 2000, pp. 105-119, © Elsevier Science B.V.
Conover et al., “Campothecin delivery systems: enhanced efficacy and tumor accumulation of campotothecin following its conjugation to polyethylene glycol via a glycine linker,”Cancer Chemother Pharmacol, vol. 42, 1998, pp. 407-414, © Springer-Verlag.
Conover et al., “Camptothecin Delivery Systems: The Utility of Amino Acid Spacers for the Conjugation of Camptothecin with Polyethylene Glycol to Create Prodrugs,”Anti-Cancer Drug Design, vol. 14, 1999, pp. 499-506, © Oxford University Press.
Conover et al., “Camptothecin Delivery Systems: The Antitumor Activity of a Campothecin-20-0-Polyethylene Glycol Ester Transport Form,”Anticancer Research, vol. 17, 1997, pp. 3361-3368.
Cortes et al., “Docetaxel,”J. of Clinical Oncology, vol. 13, 1995, pp. 2643-2655 © American Society of Clinical Oncology.
De Vries et al., “Conjugation of Docetaxel (DTXL) to Poly L-Glutamic Acid (PG) Increases Anti-Tumor Efficacy,”Proceedings of the American Association for Cancer Research, vol. 41, 2000, p. 323, Abstract No. 2051.
De Vries et al., “CT-2103: A water soluble poly-L-glutamic acid (PG)-Paclitaxesl (TXL) conjugate has enhanced efficacy on MDR-1+human colon carcinoma cell line xenografts compared to free TXL,”AACR, 2001, Abstract No. 462.
De Vries et al., “Optimization of the anti-tumor activity of water-soluble poly L-glutamic acid (PG)-paclitaxel (TXL) conjugates,”AACR-NCI-EORTC92, 1999, p. 22, Abstract No. 451, Washington, DC.
De Vries et al., “Pharmacokinetics (PK) and biodistribution of poly-(L)-glutamic acid (PG) paclitaxesl (TXL) (CT-2103) in mice with subcutaneous B-16 melanomas,”Proceedings of the 11thAACR-NCI-EORTC Symposium, 2000 Amsterdam, Netherlands.
Deutsch et al., “Synthesis of Congeners of Prodrugs. 3. Water-Soluble Prodrugs of Taxol with Potent Antitumor Activity,”J. Med. Chem., vol. 32, 1989, pp. 788-792 © American Chemical Society.
Duncan et al., “Polymer-drug conjugates, PDEPT and PELT:basic principles for design and transfer from the Laboratory to Clinic,”Journal of Controlled Release, vol. 74, 2001, pp. 135-146, © Elsevier Science B.V.
Eiseman et al., “Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice,”Cancer Chemother. Pharmacol., vol. 34, 1994, pp. 465-471 © Springer-Verlag.
Fidler et al., “The Biology of Cancer Invasion and Metastasis,”Adv. Cancer Res., vol. 28, 1978, pp. 149-250 © Academic Press, Inc.
Gilbert et al., “Novel water soluble paclitaxel derivatives: Evaluation of PEG-paclitaxel's in vitro and in vivo effects,”Proc. Amer. Assoc. Cancer Res., vol. 38, 1997, p. 225, Abstract #1512.
Goldspiel, “Pharmaceutical Issues: Preparation, Administration, Stability, and Compatibility with Oth r Medications,”Ann. Pharmacotherapy, vol. 28, 1994, pp. S23-26, © Harvey Whitney Books Company.
Greenwald et al., “Camptothecin-20-PEG Ester Transport Forms: the Effect of Spacer Groups on Antitumor Activity,”Bioorganic&Medicinal Chemistry, vol. 6, 1998, pp. 551-562, © Elsevier Science Ltd.
Greenwald et al., “Drug Delivery Systems. 2. Camptothecin 20-0-Poly(ethylene glycol) Ester Transport Forms,”J. Med. Chem., vol. 39, 1996, pp. 1938-1940, © American Chemical Society.
Greenwald et al., “Drug Delivery Systems: Water Soluble Taxol 2′-Poly(Ethylene Glycol) Ester Prodrugs-Design and in Vivo Effectiveness,”J. Med. Chem., vol. 39, 1996, pp. 424.431 © American Chemical Society.
Greenwald et al., “Highly Water Soluble Taxol Derivatives: 2′-Polyethylene Glycol Esters as Potential Products,”J. Org. Chem., vol. 60, 1995, pp. 331-336 © American Chemi
Li Chun
Wallace Sidney
Yang David J.
Yu Dong-Fang
Foley & Lardner LLP
Hartley Michael
PG-TXL Company L.P.
LandOfFree
Water soluble paclitaxel derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Water soluble paclitaxel derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Water soluble paclitaxel derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3674985